Applied Dna Scie Stock Price, News & Analysis

Applied DNA Sciences (NASDAQ: APDN) announced positive preliminary results from a Phase I clinical trial of its LinearDNA™ COVID-19 vaccine candidate for domestic felines. Conducted in February, the trial showed that the vaccine was well-tolerated, producing high levels of SARS-CoV-2 neutralizing antibodies in all 11 participating cats. The company intends to extend the study until September 2021 to assess the durability of the immune response. Following these results, plans for Phase II trials are anticipated, focusing on vaccinated cats’ resistance to infection.

Applied DNA Sciences, Inc. (NASDAQ: APDN) announced an interview with CEO Dr. James A. Hayward on BBC’s Business Daily, focusing on traceability in cotton. The Company’s CertainT® platform authenticates materials in complex supply chains, having secured approximately 300 million pounds of North American cotton. CertainT ensures product integrity by marking cotton fibers with a unique identifier to combat illicit blending, including forced labor. The Company also commercializes its LinearDNA™ platform for diagnostics and drug development, alongside applications in supply chain security.

Applied DNA Sciences, Inc. (NASDAQ: APDN) and Northwell Health have established a pro bono Material Transfer Agreement for a real-time surveillance program to identify SARS-CoV-2 mutations. This program involves screening over 2,000 COVID-positive specimens using Applied DNA's Linea™ COVID-19 Assay Kit and Selective Genomic Surveillance™ Mutation Panel. Initial results show that approximately 80% of samples tested contain mutations. The data may aid in vaccine design and support clinical care improvements. The combination of these tools aims to optimize the use of limited next-generation sequencing resources.

Applied DNA Sciences (NASDAQ: APDN) announced the reappointment of Clay Shorrock as Chief Legal Officer and Executive Director, Business Development. Shorrock, who has over a decade of experience in intellectual property and biotechnology, will lead legal, regulatory, and business development functions. CEO Dr. James A. Hayward emphasized Shorrock's expertise and prior contributions, such as securing Emergency Use Authorization for the COVID-19 assay kit. This new leadership role is aimed at advancing the company's proprietary LinearDNA platform across multiple sectors, enhancing growth and innovation.

Applied DNA Sciences (NASDAQ: APDN) announced a purchase order for its Linea™ COVID-19 Assay Kit to conduct 10,000 tests under a Master Services Agreement. The delivery is expected primarily in the fiscal quarter ending March 31, 2021. The Assay Kit is authorized under the FDA's Emergency Use Authorization and can detect certain SARS-CoV-2 mutations. The company views this order as validation of the kit's effectiveness amid rising vaccination rates and the spread of COVID-19 variants, specifically the U.K. variant.

Applied DNA Sciences (NASDAQ: APDN) has launched its Linea™ COVID-19 Selective Genomic Surveillance™ Mutation Panel to enhance tracking of SARS-CoV-2 Variants of Concern in the U.S. This panel utilizes proprietary qPCR assays to optimize Next Generation Sequencing resources and is marketed towards government labs, hospitals, and academic institutions. The SGS Panel, currently for research use only, aims to identify significant samples for NGS analysis, thereby assisting in the management of variant spread amidst vaccine rollout. The company also aims to sequence 100 SARS-CoV-2 genomes daily, potentially doubling capacity.

Applied DNA Sciences (NASDAQ: APDN) will participate in several upcoming virtual investor conferences. Key events include a company presentation by Dr. James A. Hayward at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, and a panel discussion at Roth Capital Markets’ 33rd Annual Conference on March 15. Additionally, Dr. Hayward will present at the Inaugural Emerging Growth Virtual Conference on March 17-19. These presentations will be accessible via the company’s website.

Applied DNA Sciences (NASDAQ: APDN) has initiated Phase I of its clinical trial for a LinearDNA™ COVID-19 vaccine aimed at felines. The trial evaluates the vaccine's safety and immunogenicity, targeting the prevention of SARS-CoV-2 transmission from cats to humans. Following successful Phase I results, Applied DNA and Evvivax plan to progress to Phase II, with the potential to apply for a USDA APHIS conditional license for commercial sales. The trial emphasizes the significance of the vaccine in preventing zoonotic transmission, with approximately 58.4 million cats in the U.S.

Applied DNA Sciences (NASDAQ: APDN) announced the issuance of United States Patent No. 10,920,274 for methods of authenticating objects using nucleic acid-coated submicron particles. The patent enhances the company's strong intellectual property portfolio, which now includes 92 issued patents and 40 pending applications. Dr. James Hayward, President and CEO, emphasized the patent's importance for their CertainT® platform in combating counterfeit pharmaceuticals and nutraceuticals. Applied DNA continues to focus on their LinearDNA™ platform across various markets, including diagnostics and anti-counterfeiting.